Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial StatsDark mode
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT00336843
Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma
Overview
In order to improve the clinical result of high-dose chemotherapy and autologous stem cell transplantation for B-cell non-Hodgkin's lymphoma, Zevalin will be added to the conditioning regimen. Investigators expect this radioimmunotherapy of Zevalin plus busulfan, cyclophosphamide and etoposide regimen will improve survival of relapsed or poor-risk B-cell non-Hodgkin's lymphoma.
Sponsor
Asan Medical Center
Phase
Phase 2
Contacts
Cheolwon Suh, MD, PhD (PRINCIPAL_INVESTIGATOR)
ClinicalTrials.gov
NCT00336843Drug / Compound
ibritumomab tiuxetan
Isotope(s):
YTTRIUM-90
Radioisotope: Y-90
Theranostic Role: Therapeutic Agent, SPECT Imaging & PET Imaging
T1/2 (Half-Life): 2.7 Days
Decay Mode: BETA
Energy: max 2.2 MeV
Range: In Tissue: Avg 2.5 mm, Max 11 mm; In Air: 35 feet
Decay Daughters: Zr90 (Stable)
Status: FDA Approvals: SIR-SPHERES® (2000), THERASPHERES® (2021)
Target(s):
- cd20
Ligand Class: Antibodies
Chelator: tiuxetan
Eligibility
Inclusion
- Histologically confirmed B-cell NHL in chemotherapy-sensitive relapse, in partial response to 1st line chemotherapy, or in complete response after 1st line chemotherapy with high IPI score at diagnosis
- Optimal harvest of autologous stem cells (CD34+ cells \> 5 million/kg plus 2 million/kg for back-up)
- Bilirubin \< 2 mg/dL
- Transaminase \< 3X upper normal value
- Life expectancy of at least 3 months
- ANC \> 1,500/mm3, platelet \> 100,000/mm3
- WHO performance status (PS) of 0-2
- Cr \< 2.0 mg% or Ccr \> 50 mL/min
Exclusion
- Prior biologic or immunotherapy less than 4 weeks prior to entry on this study
- Pregnant or breast feeding female patients, adults without effective contraception up to 12 months after RIT
- Investigational drugs less than 4 weeks prior to entry on this study
- Known hypersensitivity to murine antibodies/proteins
- CNS involvement of non-Hodgkin's lymphoma
- Prior external radiation to \> 25% of active bone marrow
- HIV or HTLV-1 associated malignancy
- Persistent toxic side effects from prior therapy
- Prior RIT
- Serious comorbid diseases
- Prior hematopoietic stem cell transplantation
Share your feedback
Help us improve your experience